Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Veklury Drives 2Q Growth for Gilead | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Veklury Drives 2Q Growth for Gilead

Veklury (remdesivir) with sales of $829 million offsets loss of exclusivity of Truvada and Atripla in the U.S. with sales down 72% and 42%, respectively.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Gilead
2Q Revenues: $6.2 billion (+21%)
2Q Earnings: $1.5 billion (loss of $3.3 billion 2Q20)
Comments: Growth in the quarter was primarily due to Veklury (remdesivir), with sales of $829 million, higher demand for Biktarvy and hepatitis C virus (HCV) products, and continued uptake in the U.S. of Trodelvy and Tecartus.

Product sales excluding Veklury increased 5% to $5.3 billion in the quarter, offset by loss of exclusivity of Truvada and Atripla in the U.S. with sales down 72% to $108 million and 42% to $60 million, respectively. HIV product sales decreased 2% to $3.9 billion. Biktarvy sales increased 24% and Descovy sales increased 4%. HCV product sales increased 23% to $549 million.

Hepatitis B virus (HBV) and hepatitis delta virus (HDV) product sales increased 8% to $237 million. Vemlidy sales increased 32% driven by increased demand outside the U.S. and Europe. Hepcludex contributed $7 million in the quarter reflecting the first full quarter of sales.
 
Cell Therapy product sales increased 39% to $219 million. Yescarta (axicabtagene ciloleucel) sales increased to $178 million, reflecting continued uptake in relapsed or refractory indolent follicular lymphoma following FDA approval and expansion in Europe. Tecartus sales were $41 million in the quarter, driven by the launch in mantle cell lymphoma in the U.S. and Europe.
 
Trodelvy sales were $89 million with launch activities continuing following full FDA approval for second-line metastatic triple-negative breast cancer (mTNBC) and accelerated approval for metastatic urothelial cancer. Other product sales increased 20% to $291 million.

Read Contract Pharma’s Top Companies Report on Gilead.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters